Evidence map›Paper›PMID 26061179›Full record

Observational studyPloS one2015

High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.

Jih-Luh Tang, Hsiang-Chi Kung, Weng-Chi Lei, Ming Yao, Un-In Wu, Szu-Chun Hsu, Chien-Ting Lin, Chi-Cheng Li, Shang-Ju Wu, Hsin-An Hou and 8 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. State of the art ofClinical and translational imaging · 2021
    Review
  10. Invasive Fungal Diseases in Children with Acute Leukemia and Severe Aplastic Anemia.Mediterranean journal of hematology and infectious diseases · 2021
    Article
  11. Antifungal activity of liriodenine on agents of systemic mycoses, with emphasis on the genusThe journal of venomous animals and toxins including tropical diseases · 2020
    Article
  12. Article
  13. Article
  14. A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020
    Article
  15. Review
  16. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  17. Fungal Diseases in Taiwan-National Insurance Data and Estimation.Journal of fungi (Basel, Switzerland) · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jih-Luh TangDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan; Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Hsiang-Chi KungDivision of Infection, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Weng-Chi LeiDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Ming YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Un-In WuClinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan.
Szu-Chun HsuDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chien-Ting LinTai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Chi-Cheng LiTai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Shang-Ju WuDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Wen-Chien ChouDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shang-Yi HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Woei TsayDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Yao-Chang ChenDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yee-Chun ChenDivision of Infection, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan; National Institute of Infectious Diseases and Vaccinology, National health Research Institute, Miaoli, Taiwan.
Shan-Chwen ChangDivision of Infection, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive fungal infections (IFIs) is an important complication for acute myeloid leukemia (AML) patients receiving induction chemotherapy. However, the epidemiological information is not clear in Southeastern Asia, an area of potential high incidences of IFIs. To clarify it, we enrolled 298 non-M3 adult AML patients receiving induction chemotherapy without systemic anti-fungal prophylaxis from Jan 2004 to Dec 2009, when we applied a prospective diagnostic and treatment algorithm for IFIs. Their demographic parameters, IFI characters, and treatment outcome were collected for analysis. The median age of these patients was 51 years. Standard induction chemotherapy was used for 246 (82.6%) patients, and 66.8% of patients achieved complete remission (CR) or partial remission. The incidence of all-category IFIs was 34.6% (5.7% proven IFIs, 5.0% probable IFIs and 23.8% possible IFIs). Candida tropicalis was the leading pathogen among yeast, and lower respiratory tract was the most common site for IFIs (75.4%, 80/106). Standard induction chemotherapy and failure to CR were identified as risk factors for IFIs. The presence of IFI in induction independently predicted worse survival (hazard ratio 1.536 (1.100-2.141), p value = 0.012). Even in those who survived from the initial IFI insults after 3 months, the presence of IFIs in induction still predicted a poor long-term survival. This study confirms high incidences of IFIs in Southeastern Asia, and illustrates potential risk factors; poor short-term and long-term outcomes are also demonstrated. This epidemiological information will provide useful perspectives for anti-fungal prophylaxis and treatment for AML patients during induction, so that best chances of cure and survival can be provided.

Indexed as

AdolescentAdultAgedAged, 80 and overAntifungal AgentsFemaleHumansInduction ChemotherapyLeukemia, Myeloid, AcuteMaleMiddle AgedMycosesPre-Exposure ProphylaxisProspective StudiesRemission InductionRisk FactorsAntifungal Agents

Identifiers

PMID26061179
PMCPMC4462587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.